about
Genetic dissection of the human leukocyte antigen region by use of haplotypes of Tasmanians with multiple sclerosisGenetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosisBrain health: time matters in multiple sclerosisCountry, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndromeThe Australian Multiple Sclerosis (MS) immunotherapy study: a prospective, multicentre study of drug utilisation using the MSBase platformA polymorphism in the HLA-DPB1 gene is associated with susceptibility to multiple sclerosisA new era in the treatment of multiple sclerosisGenome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci.Observational data: Understanding the real MS world.Optic nerve magnetisation transfer ratio after acute optic neuritis predicts axonal and visual outcomes.Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association oMultiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients.On the utility of data from the International HapMap Project for Australian association studies.A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data.Altered topological organization of white matter structural networks in patients with neuromyelitis optica.Data quality evaluation for observational multiple sclerosis registries.Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase RegistryBlocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve.Vaginally administered PEGylated LIF antagonist blocked embryo implantation and eliminated non-target effects on bone in mice.Combined peripheral nerve and central nervous system demyelination in a patient with chronic inflammatory demyelinating polyneuropathy.Continuing fingolimod after development of macular edema: A case report.Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results.Leukemia inhibitory factor protects axons in experimental autoimmune encephalomyelitis via an oligodendrocyte-independent mechanism.Geographical variations in sex ratio trends over time in multiple sclerosis.Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study.EphA4 receptor tyrosine kinase is a modulator of onset and disease severity of experimental autoimmune encephalomyelitis (EAE)Suppressor of cytokine signaling 3 limits protection of leukemia inhibitory factor receptor signaling against central demyelination.Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon beta 1a dosages for multiple sclerosisValidation of a novel biomarker for acute axonal injury in experimental autoimmune encephalomyelitis.Prospects for stem cell transplantation in multiple sclerosis.Fine mapping of multiple sclerosis susceptibility genes provides evidence of allelic heterogeneity at the IL2RA locus.Optic nerve diffusion tensor imaging after acute optic neuritis predicts axonal and visual outcomesAxonally derived matrilin-2 induces proinflammatory responses that exacerbate autoimmune neuroinflammation.Comparative efficacy of switching to natalizumab in active multiple sclerosis.Predictors of disability worsening in clinically isolated syndrome.Parallel changes in structural and functional measures of optic nerve myelination after optic neuritis.Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MSThe MS Risk Allele of CD40 Is Associated with Reduced Cell-Membrane Bound Expression in Antigen Presenting Cells: Implications for Gene FunctionSwitching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMSEpoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP)
P50
Q24563911-AFA80494-23A1-404C-B613-76F480748843Q24635370-CC1AB58F-2545-4F29-A97B-33F1AD1C1CA9Q28076642-F0063360-7A99-496E-B366-A3600474313EQ28480907-9D76DD4B-2029-43E7-9790-CC934122E163Q28488248-CCDC6E4F-D978-4E29-A26C-3B63CACFC99BQ28748710-43543140-E5E5-43FB-9E7F-65710D91790CQ29395420-8CE9B3AC-5972-4A11-B0FF-DA091CFF2E8CQ29417047-EAF46E64-57F3-49F2-9A78-941FADFA6887Q30249781-A386A454-3261-4D10-A954-5DF55B773B48Q30583486-9CB000AE-84E4-4EC4-8217-A7036C89EE20Q30834551-D2FE1225-3243-4973-82C3-5906EB4D86F1Q30980357-2474D817-196C-4343-A259-59E0F2F53DBEQ31029393-3DBC6812-F608-4ACF-9BAC-AB0F6952D656Q31034192-79FD6E52-8889-40E8-916C-B7A54E4150FAQ31106733-B082C8E7-D4E7-4C1E-9B08-CB19433699DFQ31119031-6740DFA6-0DED-42D2-A843-7110373389DAQ33613668-D8188F7F-C8D4-4EC1-8D90-2F1E83D55D59Q33692583-8769FDBF-E9E4-4C75-BD9C-7E15A360A86CQ33911059-50B36495-A8B2-46BE-8B81-63C855AD71EEQ33938284-13737CD7-A360-4A4D-B12A-FD77A7C83057Q34368552-981F9632-970B-41CE-934E-341C01AF1F9FQ34431300-655FE4FA-6BB6-4A1E-A178-C48AB105EDA9Q34450780-3965C2FC-7048-47ED-BE77-40EEBEE17E6EQ34469310-443B59B5-560E-4661-8928-1D62D63E79E0Q34536052-8F9DA6B0-5BBD-496D-994D-1CFB4D56E2E6Q34580168-97148935-2D08-4876-A936-04FB4DF799FDQ34650995-8502FBC8-E1AE-4C9A-BF74-4D8BE4962B13Q34737478-8F95A14E-163C-4A7F-84C8-ABFF30C908F5Q34809963-A4283DA4-CE1A-499F-ACA3-495678149E12Q34826291-B3A82FCA-1232-4E3E-8554-0550397DAE01Q34976409-349F611C-6006-4526-ABFF-828D20C6994BQ35080681-C6C0A20E-57B5-49C9-BCFC-F451834A24D1Q35140044-64970C5A-EF59-4D48-88DB-C047D01ACB0BQ35469575-AE91EA93-3F26-4B51-807E-AB4BFBCDB435Q35619185-860DFAD2-0929-40F3-819F-84FAA3B85684Q35645061-C734783C-EA29-496C-AECA-F3D1D0C1E1A6Q35653675-6AFCD21F-00AA-42B1-B0AF-8585477C207FQ35661793-67210C3E-D48C-477C-9CD6-D6EF8C4D0B01Q35850708-82B23C6D-4DEC-4B94-BA68-67C021A66DC0Q35895287-C6D7B38A-A4B4-4938-9859-F7E728FFEAA4
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Helmut Butzkueven
@ast
Helmut Butzkueven
@en
Helmut Butzkueven
@es
Helmut Butzkueven
@nl
Helmut Butzkueven
@sl
type
label
Helmut Butzkueven
@ast
Helmut Butzkueven
@en
Helmut Butzkueven
@es
Helmut Butzkueven
@nl
Helmut Butzkueven
@sl
prefLabel
Helmut Butzkueven
@ast
Helmut Butzkueven
@en
Helmut Butzkueven
@es
Helmut Butzkueven
@nl
Helmut Butzkueven
@sl
P106
P1153
6602146136
P21
P31
P496
0000-0003-3940-8727